CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives

Malar J. 2010 Jul 13:9:202. doi: 10.1186/1475-2875-9-202.

Abstract

Despite increasing efforts and support for anti-malarial drug R&D, globally anti-malarial drug discovery and development remains largely uncoordinated and fragmented. The current window of opportunity for large scale funding of R&D into malaria is likely to narrow in the coming decade due to a contraction in available resources caused by the current economic difficulties and new priorities (e.g. climate change). It is, therefore, essential that stakeholders are given well-articulated action plans and priorities to guide judgments on where resources can be best targeted.The CRIMALDDI Consortium (a European Union funded initiative) has been set up to develop, through a process of stakeholder and expert consultations, such priorities and recommendations to address them. It is hoped that the recommendations will help to guide the priorities of the European anti-malarial research as well as the wider global discovery agenda in the coming decade.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials / economics*
  • Antimalarials / therapeutic use
  • Drug Discovery / economics*
  • Drug Discovery / organization & administration
  • Drug Resistance
  • European Union
  • Health Policy
  • Health Priorities*
  • Humans
  • Malaria* / drug therapy
  • Malaria* / prevention & control
  • Plasmodium / drug effects
  • Research / economics*
  • Research / trends

Substances

  • Antimalarials